Results 211 to 220 of about 74,688 (254)

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials [PDF]

, 2017
et al,, Mutch, David G
core   +1 more source

Cost-effectiveness analysis of belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma in the United States and China. [PDF]

Ther Adv Med Oncol
Ding B, Yao H, Tao T, Sun Y, Zhu Y, Zhu H, Wang J, Jing Z, Gao L, Lin Y, Li X.   +10 more
europepmc   +1 more source

Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo

Gerke Ariaans, Jiske F. Tiersma, Bernard Evers, Albert Gerding, Stijn J.H. Waaijer, Remco A. Koster, Daan J. Touw, Barbara M. Bakker, Dirk‐Jan Reijngoud, Steven de Jong, Mathilde Jalving   +10 more
openalex   +2 more sources

Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents

, 2016
Yohei Sotomi, Yuki Ishibashi, Pannipa Suwannasom, Shimpei Nakatani, Yun‐Kyeong Cho, Maik J. Grundeken, Yaping Zeng, Hiroki Tateishi, Pieter C. Smits, Paul Barragan, Ran Kornowski, Anthony Gershlick, Stephan Windecker, Robert‐Jan van Geuns, Antonio L. Bartorelli, Robbert J. de Winter, Jan Tijssen, Patrick W. Serruys, Yoshinobu Onuma   +18 more
openalex   +2 more sources

Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2- Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy. [PDF]

Curr Oncol
Altıntaş YE, Kınıkoğlu O, Işık D, Batu A, Bayramgil A, Niğdelioğlu B, Özkerim U, Öksüz S, Sürmeli H, Turan N, Odabaş H.   +10 more
europepmc   +1 more source

SPIRIT Women, evaluation of the safety and efficacy of the XIENCE V everolimus-eluting stent system in female patients: referral time for coronary intervention and 2-year clinical outcomes

, 2012
Marie‐Claude Morice, Ghada Mikhail, Fina Mauri i Ferré, Maria Grazia Modena, Ruth H. Strasser, Liliana Grinfeld, Krishnankutty Sudhir, Marrianne Stuteville, Peggy Papeleu, Dong Li, David R. Rutledge, Stephan Windecker   +11 more
openalex   +2 more sources

Targeting the PI3K/AKT/mTOR signaling pathway in prostate cancer: Molecular dysregulation, therapeutic advances, and future directions. [PDF]

Saudi Pharm J
Alobid S.
europepmc   +1 more source

The Twelve-Month Outcome of Biolimus Eluting Stent with Biodegradable Polymer Compared With an Everolimus Eluting Stent with Durable Polymer

, 2011
Ahmad Separham, Bahram Sohrabi, Naser Aslanabadi, Samad Ghaffari   +3 more
openalex   +1 more source

Outcomes of everolimus-treated HR+/HER2- breast cancer. [PDF]

J Chin Med Assoc
Wang PH, Yang ST, Kuo TC.
europepmc   +1 more source

Influencia del sexo en los resultados clínicos de los stents liberadores de everolimus en comparación con los stents metálicos sin recubrimiento en el infarto agudo de miocardio con elevación del segmento ST. Perspectivas del ensayo EXAMINATION

, 2014
Ander Regueiro, Diego Fernández-Rodríguez, Salvatore Brugaletta, Victoria Martín‐Yuste, Mónica Masotti, Xavier Freixa, Ángel Cequier, Andrés Íñiguez, Patrick W. Serruys, Manel Sabaté   +9 more
openalex   +2 more sources